Kymera Therapeutics (KYMR) Assets (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Assets of $1.7 billion for Q1 2026, up 81.75% year-over-year from $918.3 million in Q1 2025, and down 4.23% quarter-over-quarter from $1.7 billion in Q4 2025.
Kymera Therapeutics (KYMR) Assets (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Assets for 8 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 81.75% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (up 81.75% YoY), while the FY2025 annual figure was $1.7 billion, up 78.2% from the prior year.
- Assets retreated to $1.7 billion in Q1 2026 per KYMR's latest filing, from $1.7 billion in the prior quarter.
- Across five years, Assets topped out at $1.7 billion in Q4 2025 and bottomed at $523.4 million in Q2 2022.
- Historically, Assets has averaged $877.8 million across 5 years, with a median of $826.0 million in 2024.
- Annual changes were most pronounced in 2023 — Assets fell 13.48% — and 2024, when it surged 87.34%.
- Kymera Therapeutics' Assets stood at $603.1 million in 2022, then slipped by 4.54% to $575.8 million in 2023, then jumped by 69.87% to $978.0 million in 2024, then jumped by 78.2% to $1.7 billion in 2025, then decreased by 4.23% to $1.7 billion in 2026.
- Business Quant data shows KYMR's Assets at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 1.65 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.65 Bn |
| Mar 31, 2026 | 1.67 Bn |
| Dec 31, 2025 | 1.74 Bn |
| Sep 30, 2025 | 1.10 Bn |
| Jun 30, 2025 | 1.13 Bn |
| Mar 31, 2025 | 918.31 Mn |
| Dec 31, 2024 | 978.04 Mn |
| Sep 30, 2024 | 1.03 Bn |
| Jun 30, 2024 | 826.02 Mn |
| Mar 31, 2024 | 868.25 Mn |
| Dec 31, 2023 | 575.76 Mn |
| Sep 30, 2023 | 552.38 Mn |
| Jun 30, 2023 | 581.95 Mn |
| Mar 31, 2023 | 613.91 Mn |
| Dec 31, 2022 | 603.13 Mn |
| Sep 30, 2022 | 638.47 Mn |
| Jun 30, 2022 | 523.42 Mn |
| Mar 31, 2022 | 563.06 Mn |
| Dec 31, 2021 | 605.91 Mn |
| Sep 30, 2021 | 642.45 Mn |